Rubius Therapeutics, Inc. (RUBY): Price and Financial Metrics
Rubius Therapeutics, Inc. (RUBY)
Today's Latest Price: $8.92 USD
Updated Jan 17 12:00am
Add RUBY to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
RUBY Stock Price Chart More Charts
RUBY Price/Volume Stats
| Current price | $8.92 | 52-week high | $20.04 |
| Prev. close | $9.84 | 52-week low | $6.96 |
| Day low | $8.81 | Volume | 544,600 |
| Day high | $10.05 | Avg. volume | 534,058 |
| 50-day MA | $9.96 | Dividend yield | N/A |
| 200-day MA | $12.17 | Market Cap | 711.82M |
Rubius Therapeutics, Inc. (RUBY) Company Bio
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Top Stories View All
Best & Worst Performing Stock Industries for January 20, 2020
Best & Worst Performing Small Cap Stocks for January 20, 2020
Best & Worst Performing Mid Cap Stocks for January 20, 2020
Best & Worst Performing Large Cap Stocks for January 20, 2020
Best & Worst Performing Mega Cap Stocks for January 20, 2020
View All Top Stories
Loading social stream, please wait...